| Description |
Recombinant Mouse SEMA4B Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Leu31-Glu703. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q62179 |
| Target Symbol |
SEMA4B |
| Synonyms |
Semaphorin-4B; Semaphorin-C; SEMA4B; KIAA1745; SEMAC; MGC131831; SemC |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
C-His |
| Expression Range |
Leu31-Glu703 |
| Mol. Weight |
The protein has a predicted MW of 75.7 kDa. Due to glycosylation, the protein migrates to 78-83 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Semaphorin 4B (SEMA4B) inhibits the invasion of non-small cell lung cancer (NSCLC) through PI3K-dependent suppression of MMP9 activation. SEMA4B may induce FoxO1 nuclear retention through suppressing PI3K/Akt signaling pathway, which subsequently inhibited cell growth through the direct nuclear target of FoxO1, p21. A role of SEMA4B in suppressing NSCLC growth, besides its role in inhibiting cell metastasis, and highlights SEMA4B as a promising therapeutic target for NSCLC. |
